Alembic Pharmaceuticals Ltd

BSE: 533573

total announcements

533573.BO · 15 min delayed

BSECompany Update▲ PositiveOrder Win1d ago

Alembic Pharmaceuticals Limited receives USFDA Final approval for Prucalopride Tablets, 1 mg and 2 mg.

Alembic Pharmaceuticals Ltd has received USFDA final approval for Prucalopride Tablets, 1 mg and 2 mg, a treatment for chronic idiopathic constipation in adults, with an estimated market size of $100 million.

Please find attached herewith Intimation for Investors Call Scheduled to be held on 4th August, 2026.

Alembic Pharmaceuticals Ltd has announced a conference call to discuss its Q1 FY27 unaudited financial results on August 4, 2026. The call will be held at 5:30 P.M. IST and can be accessed through a registration link or by dialing into a conference line.

Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve Unaudited Financial ....

Alembic Pharmaceuticals Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 to consider and approve Unaudited Financial Results for the quarter ended 30th June, 2026.